Guardion Health Sciences, Inc.: management transactions · United States · SEC (Form 4)

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. is a U.S.-listed company on the Nasdaq Stock Market LLC under the ticker GHSI. The company is incorporated in the United States and has historically referenced Houston, Texas, as its operational headquarters, while its early manufacturing and product-development footprint was tied to California, including the San Diego/Irvine area. Guardion was formed in December 2009 as P4L Health Sciences, LLC and later converted into a Delaware corporation in 2015, reflecting a typical evolution from private operating entity to public-market issuer. Guardion’s business is centered on clinical nutrition and ocular health. The company has positioned itself as a specialty health sciences platform focused on science-based, clinically supported products for consumer eye health. Its current commercial emphasis includes Lumega-Z and GlaucoCetin, both marketed as ocular-health nutrition products. Lumega-Z was reformulated and relaunched in March 2024 as a drink-mix powder at a lower retail price than the prior liquid formulation, a move designed to improve accessibility, support existing customers, and broaden the addressable consumer base. Guardion sells these products through its own digital channels and addresses consumers, healthcare professionals, providers, and their patients. Over time, the company has also built out a broader ophthalmic and diagnostic-related heritage. Earlier product development included MapcatSF, a device designed to measure macular pigment optical density. In 2017, Guardion acquired substantially all of the assets of VectorVision, a business focused on standardization tools for contrast sensitivity, glare sensitivity, low-contrast acuity, and ETDRS visual acuity testing. That history suggests the company has tried to combine nutrition-based products with diagnostic and measurement capabilities, although the current commercial profile appears much narrower than in prior years. From a competitive standpoint, Guardion operates in a niche market where clinical credibility, brand trust, and product differentiation matter more than scale. It is small relative to large nutrition, consumer-health, or ophthalmology companies, but it can potentially benefit from specialization in eye health and from products that are marketed as science-backed and clinically supported. The trade-off is clear: the company’s narrow product set and limited scale create dependence on a small number of offerings and heighten execution risk. Recent developments have been material. In 2024, Guardion announced the reformulation and relaunch of Lumega-Z. The company also disclosed a proposed sale of the Viactiv brand and business and a plan of liquidation and dissolution, signaling a major strategic reset and possible wind-down of legacy operations. Quarterly filings in 2024 showed modest revenues and underscore the company’s micro-cap profile. For investors following U.S. insider activity and SEC Form 4 filings, Guardion Health Sciences remains a highly specialized, small-cap healthcare name on Nasdaq in the United States, with a story defined by restructuring, niche ocular-health products, and strategic uncertainty.